Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. (2nd January 2018)

• Record Type: Journal Article
• Authors: Kavanagh, Simon; Nee, Aisling; Lipton, Jeffrey H.
• Is Part Of: Expert opinion on emerging drugs. Volume 23:Number 1(2018)
• Page Start: 51
• Page End: 62
• Publication Date: 2018-01-02
• Subjects: Chronic myeloid leukemia -- tyrosine kinase -- BCR-ABL -- non-targeted therapy; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2018.1445717
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction : BCR-ABL-directed tyrosine kinase inhibitors (TKIs) have revolutionised therapy for chronic myeloid leukemia. However, despite the availability and efficacy of this class of agents, lifelong treatment is still required in a significant proportion of patients Areas covered : We give an overview of the currently available BCR-ABL-directed TKIs and other conventional therapies for CML. We proceed to review the current market and some of the scientific rationale for new drug development before outlining a number of novel therapies, considered broadly as immunotherapies and targeted agents. Published English-language literature was reviewed regarding currently available TKIs; clinical trials repositories were reviewed to identify novel agents recently investigated or under active study. Expert opinion : We recommend discussion with patients and enrolment on an appropriate clinical trial where feasible. In situations where no trials are available, or if patients decline enrolment, we recommend use of an appropriate BCR-ABL directed TKI, selected on the basis of an evaluation of patient risk factors and side effect profile. Allogeneic stem cell transplant continues to have a role though this is generally limited to cases with advanced phases of disease or in cases with resistance-conferring mutations.